Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET.
Marion ChometMaxime SchreursMaria J BolijnMariska VerlaanWissam BeainoKari BrownAlex J PootAlbert D WindhorstHerman GillJan MarikSimon WilliamsJoseph CowellGilles GasserThomas L MindtGuus A M S van DongenDanielle J VugtsPublished in: European journal of nuclear medicine and molecular imaging (2020)
DFO*-mAb conjugates provide lower bone uptake than their DFO analogues; thus, DFO* is a superior candidate for preclinical and clinical 89Zr-immuno-PET.